Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHI-101 in Platinum-Resistant/Refractory Ovarian Cancer
NCT04678102Phase 1Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lasmotinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (6 cohorts), sponsored by Seoul National University Hospital. Primary endpoints: Dose-Limiting Toxicity and Maximum Tolerated Dose. Status: unknown.
02
Drugs
lasmotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04678102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678102.